Article
Endocrinology & Metabolism
Cristina Lamas, Rosa Camara, Carmen Fajardo, Pablo Remon-Ruiz, Betina Biagetti, Fernando Guerrero-Perez, Marta Araujo-Castro, Mireia Mora, Felicia Hanzu, Pedro Iglesias, Rogelio Garcia-Centeno, Alfonso Soto
Summary: In this retrospective study, temozolomide was found to be an effective medical treatment for aggressive pituitary neuroendocrine tumors and pituitary carcinomas, but may sometimes lead to tumor progression. Co-administration with radiotherapy may increase progression-free survival.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Endocrinology & Metabolism
Stephanie Du Four, Jorn Van Der Veken, Johnny Duerinck, Elle Vermeulen, Corina E. E. Andreescu, Michael Bruneau, Bart Neyns, Van Velthoven, Brigitte Velkeniers
Summary: In this article, we report a case series of five patients with pituitary carcinoma (PC) and highlight the challenges in diagnosis and treatment. PCs are rare intracranial neoplasms that usually develop from aggressive pituitary adenomas. The mean time interval from initial diagnosis to PC diagnosis was 10.7 years. Various treatment approaches, including surgery, radiotherapy, temozolomide, and immunotherapy, were used, with some patients achieving stable disease. The lack of predictive factors for an aggressive clinical course makes management challenging for PCs.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Stephan Gaillard, Sosthene Adeniran, Chiara Villa, Anne Jouinot, Marie-Laure Raffin-Sanson, Loic Feuvret, Pierre Verrelle, Fideline Bonnet, Anthony Dohan, Jerome Bertherat, Guillaume Assie, Bertrand Baussart
Summary: The management of giant pituitary tumors is complex and requires a multi-modal approach, with surgery playing a central role. A multidisciplinary expert team can achieve tumor control and improve visual outcomes in the majority of patients.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Antonio Bianchi, Sabrina Chiloiro, Antonella Giampietro, Simona Gaudino, Rosalinda Calandrelli, Ciro Mazzarella, Carmelo Caldarella, Mario Rigante, Marco Gessi, Liverana Lauretti, Laura De Marinis, Alessandro Olivi, Alfredo Pontecorvi, Francesco Doglietto
Summary: Growth hormone-secreting adenomas exhibit a wide range of behaviors and outcomes, from mild disease to aggressive neoplasms. Treatment for patients who do not respond to surgery or first-generation somatostatin receptor ligands may involve multiple surgical, medical, and radiation treatments. Currently, there are no markers that can predict the prognosis or aggressiveness of acromegaly. A multidisciplinary approach is necessary to tailor treatment for difficult/aggressive cases, including radiation therapy, chemotherapy, and emerging treatments.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Clinical Neurology
Sam Ng, Mahmoud Messerer, Julien Engelhardt, Michael Bruneau, Jan Frederick Cornelius, Luigi Maria Cavallo, Giulia Cossu, Sebastien Froelich, Torstein R. Meling, Dimitrios Paraskevopoulos, Henry W. S. Schroeder, Marcos Tatagiba, Idoya Zazpe, Moncef Berhouma, Roy T. Daniel, Edward R. Laws, Engelbert Knosp, Michael Buchfelder, Henri Dufour, Stephane Gaillard, Timothee Jacquesson, Emmanuel Jouanneau
Summary: Aggressive pituitary neuroendocrine tumors (APT) account for 10% of pituitary tumors and their management is rapidly evolving. The new term Pituitary neuroendocrine tumors (PitNet) reflects a shift towards a neuro-oncological-like approach. Treatment recommendations include surgery, temozolomide, local radiotherapy, and novel therapies such as VEGF-targeted therapies and immunotherapies.
ACTA NEUROCHIRURGICA
(2021)
Article
Endocrinology & Metabolism
Andrew L. Lin, Eliza B. Geer, Nupur Lala, Gabrielle Page-Wilson, Rajiv Magge, Robert J. Young, Viviane Tabar
Summary: Everolimus shows promise as an active agent in the treatment of aggressive prolactinomas, as evidenced by biochemical response and clinical benefit in patients. Further investigation is warranted to explore its efficacy.
Article
Endocrinology & Metabolism
Pablo Remon-Ruiz, Eva Venegas-Moreno, Elena Dios-Fuentes, Juan Manuel Canelo Moreno, Ignacio Fernandez Pena, Miriam Alonso Garcia, Miguel Angel Japon-Rodriguez, Florinda Roldan, Elena Fajardo, Ariel Kaen, Eugenio Cardenas Ruiz-Valdepenas, David Cano, Alfonso Soto-Moreno
Summary: Imaging and pathology evaluation may not accurately predict the aggressiveness of pituitary tumors, but histological examination can provide useful information. Our case report highlights the importance of suspicion for malignancy in pituitary tumors with aggressive features and the need for multidisciplinary team follow-up to manage potential metastases.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Arthur Petat, Eric Dansin, Fabien Calcagno, Laurent Greillier, Eric Pichon, Mallorie Kerjouan, Christelle Clement-Duchene, Bertrand Mennecier, Virginie Westeel, Francois Thillays, Xavier Quantin, Youssef Oulkhouir, Luc Thiberville, Charles Ricordel, Vincent Thomas De Montpreville, Lara Chalabreysse, Veronique Hofman, Thierry Molina, Pierre Fournel, Laurence Bigay Game, Benjamin Besse, Nicolas Girard
Summary: This study utilized the RYTHMIC database to analyze baseline characteristics, treatment strategies, and outcomes of patients with thymic carcinoma, highlighting the need for optimized multidisciplinary management and innovative therapies.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Clinical Neurology
Sanjit Shah, Saima Manzoor, Yehudit Rothman, Matthew Hagen, Luke Pater, Karl Golnik, Abdelkader Mahammedi, Andrew L. L. Lin, Ruchi Bhabhra, Jonathan A. A. Forbes, Soma Sengupta
Summary: This is a case report highlighting the utility of immunotherapy in treating aggressive pituitary adenomas (APAs). The patient experienced complete resolution of recurrent APA and improved survival compared to the expected life expectancy. APAs are tumors with frequent recurrence and short median expected length of survival.
Review
Oncology
Peng Du, Xuefan Wu, Kun Lv, Ji Xiong, Daoying Geng
Summary: Pituitary carcinoma is a rare and difficult-to-diagnose disease, with conventional treatments showing limited effectiveness. This article reports a case of sparsely granulated somatotroph carcinoma with a favorable treatment response to temozolomide combined with radiation therapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Taohui Ouyang, Na Zhang, Shenhao Xie, Bin Tang, Junjun Li, Limin Xiao, Fabao Zhang, Bowen Wu, Dongwei Zhou, Meihua Li, Tao Hong
Summary: The study retrospectively analyzed outcomes and complications in 102 patients with Knosp grade 4 pituitary adenomas. It found that patients with complete resection of the entire tumor were more likely to have favorable endocrine and visual outcomes, and that recurrent tumors and firm consistency tumors were adverse factors for complete resection.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Pascal K. C. Jonker, John Turchini, Schelto Kruijff, Jia Feng Lin, Anthony J. Gill, Thomas Eade, Ahmad Ahniss, Roderick Clifton-Bligh, Diana Learoyd, Bruce Robinson, Venessa Tsang, Anthony Glover, Stanley Sidhu, Mark Sywak
Summary: Multimodality treatment may improve locoregional control, progression-free survival, and overall survival in selected anaplastic thyroid cancer patients, including those with stage IVC tumors, but comes with a greater complication risk.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Clinical Neurology
James R. Janopaul-Naylor, Manali Rupji, Jim Zhong, Bree R. Eaton, Naba Ali, Adriana G. Ioachimescu, Nelson M. Oyesiku, Hui-Kuo G. Shu
Summary: Modern LINAC RT is safe and effective for hormonal control and LC in patients with PAs. There was an increase in the proportion of patients requiring pituitary hormone replacement after RT.
WORLD NEUROSURGERY
(2022)
Review
Endocrinology & Metabolism
Eliza B. Geer
Summary: Refractory pituitary adenomas are those that have progressed following standard of care treatments. Medical therapy options for these challenging tumors are limited. There are currently no approved non-endocrine medical therapies for refractory pituitary tumors, highlighting the urgent need for identifying effective treatments and conducting multi-center clinical trials.
Article
Medicine, General & Internal
Yoon-Hee Choo, Youngbeom Seo, Oh-Lyong Kim
Summary: This study retrospectively analyzed the outcomes of the transsphenoidal approach for nonfunctioning pituitary adenomas treated at a single institute. The study found that the transsphenoidal approach is an effective and safe treatment, improving visual impairment and restoring endocrine function. Diabetes insipidus was the most common complication, and complete resection during surgery helped to lower the risk of recurrence.
ANNALS OF MEDICINE
(2022)